First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

The IMbrave 150 trial revealed that atezolizumab plus bevacizumab (atezo-bev) improves survival in patients with unresectable hepatocellular carcinoma (HCC) (1 year survival rate: 67.2% vs. 54.6%). We assessed the cost-effectiveness of atezo-bev vs. sorafenib as first-line therapy in patients with u...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2021-02, Vol.13 (5), p.931
Hauptverfasser:	Chiang, Chi-Leung, Chan, Sik-Kwan, Lee, Shing-Fung, Choi, Horace Cheuk-Wai
Format:	Artikel
Sprache:	eng
Schlagworte:	Bevacizumab Body weight Cancer therapies Cost analysis Cost estimates Dosage Epidemiology Hepatocellular carcinoma Immunotherapy Liver cancer Markov chains Medicare Monoclonal antibodies Mortality Patients Questionnaires R&D Research & development Software Survival Targeted cancer therapy Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!